| Title |
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis
|
|---|---|
| Published in |
Clinical Rheumatology, April 2018
|
| DOI | 10.1007/s10067-018-4069-3 |
| Pubmed ID | |
| Authors |
Claudia Fabiani, Antonio Vitale, Giacomo Emmi, Alice Bitossi, Giuseppe Lopalco, Jurgen Sota, Silvana Guerriero, Ida Orlando, Marco Capozzoli, Fiorella Fusco, Francesco Rana, Florenzo Iannone, Bruno Frediani, Mauro Galeazzi, Lorenzo Vannozzi, Gian Marco Tosi, Luca Cantarini |
| Abstract |
The aim of the present study was to compare long-term adalimumab (ADA) and infliximab (IFX) retention rates in patients with intermediate, posterior, or panuveitis. Additional aims are as follows: (i) to identify any difference in the causes of treatment discontinuation between patients treated with ADA and IFX; (ii) to assess any impact of demographic features, concomitant treatments, and different lines of biologic therapy on ADA and IFX retention rates; and (iii) to identify any correlation between ADA and IFX treatment duration and the age at uveitis onset, the age at onset of the associated systemic diseases, and the age at the start of treatment. Clinical, therapeutic, and demographic data from patients with non-infectious intermediate, posterior, or panuveitis treated with ADA or IFX were retrospectively collected. Kaplan-Meier plot and log-rank (Mantel-Cox) test were used to assess survival curves. One hundred eight patients (188 eyes) were enrolled; in 87 (80.6%) patients, uveitis was associated with a systemic disease. ADA and IFX were administered in 62 and 46 patients, respectively. No statistically significant differences were identified between ADA and IFX retention rates (p value = 0.22). Similarly, no differences were identified between ADA and IFX retention rates in relation to gender (p value = 0.61 for males, p value = 0.09 for females), monotherapy (p value = 0.08), combination therapy with conventional disease-modifying antirheumatic drugs (log-rank p value = 0.63), and different lines of biologic therapy (p value = 0.79 for biologic-naïve patients; p value = 0.81 for subjects previously treated with other biologics). In conclusion, ADA and IFX have similar long-term retention rates in patients with non-infectious intermediate, posterior, and panuveitis. Demographic, clinical, and therapeutic features do not affect their long-term effectiveness. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 16% |
| Student > Ph. D. Student | 4 | 16% |
| Other | 3 | 12% |
| Student > Bachelor | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 8 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Nursing and Health Professions | 1 | 4% |
| Psychology | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 9 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2018.
All research outputs
#20,474,896
of 23,035,022 outputs
Outputs from Clinical Rheumatology
#2,665
of 3,043 outputs
Outputs of similar age
#290,533
of 329,113 outputs
Outputs of similar age from Clinical Rheumatology
#57
of 68 outputs
Altmetric has tracked 23,035,022 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,043 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,113 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.